Anticipated $-0.11 EPS for Ionis Pharmaceuticals, Inc. (IONS) on May, 8

April 16, 2018 - By Roy Fason

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Corporate Logo

On May, 8 is expected Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)’s earnings report, RTT reports. This year’s EPS analyst estimate is expected to be $-0.11. That is 466.67 % down compareed to $0.03 EPS for last year. -650.00 % negative EPS growth is what Wall Street’s sees after $0.02 reported EPS last quarter. The stock decreased 0.34% or $0.15 during the last trading session, reaching $43.47.Currently Ionis Pharmaceuticals, Inc. is uptrending after 14.82% change in last April 17, 2017. IONS has also 494,080 shares volume. IONS outperformed by 3.27% the S&P 500.

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics.The firm is valued at $5.45 billion. The firm markets SPINRAZA, an antisense drug for spinal muscular atrophy in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and as an adjunct to lipid lowering medications and diet.Last it reported negative earnings. The Company’s drugs in Phase III development include volanesorsen for the treatment of familial chylomicronemia syndrome and familial partial lipodystrophy; and IONIS-TTRRx, an antisense drug for transthyretin amyloidosis.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.